Market Exclusive

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Results of Operations and Financial Condition

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.

Commencing on January 7, 2018, we expect to disclose the following information in discussions to be held in connection with the Annual J.P. Morgan Healthcare Conference: As of December 31, 2017, Arena Pharmaceuticals, Inc. (the “Company”) had approximately $271.0 million of cash and cash equivalents.See additional information in the presentation furnished as an Exhibit to Item 7.01.

Item 7.01 Regulation FD Disclosure.

Included as Exhibit 99.1 to this Form 8-K is a presentation titled “Corporate Presentation– JP Morgan Healthcare Conference”, dated January 2018, which is incorporated herein by reference. We intend to utilize this presentation in various meetings with securities analysts, investors and others in connection with the Annual J.P. Morgan Healthcare Conference, commencing on January 7, 2018.

The information contained in Exhibit 99.1 hereto is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ARENA PHARMACEUTICALS INC ExhibitEX-99.1 2 arna-ex991_495.htm CORPORATE PRESENTATION – JP MORGAN HEALTHCARE CONFERENCE,…To view the full exhibit click here
About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).

Exit mobile version